Literature DB >> 23194864

5-Lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid (AKBA) by a novel mechanism.

H Safayhi1, E R Sailer, H P Ammon.   

Abstract

Acetyl-11-keto-β-boswellic acid (AKAB) from Boswellia serrata and B. carterii acts directly on purified 5-lipoxygenase of human blood leukocytes at a selective site for pentacyclic triterpenes that is different from the arachidonate substrate binding site. The pentacyclic triterpene ring is crucial for binding to the enzyme, whereas functional groups (11-keto function in addition to a hydrophilic group on C 4 of ring A) are essential for the 5-lipoxygenase activity.
Copyright © 1996 Gustav Fischer Verlag · Stuttgart · Jena · New York. Published by Elsevier GmbH.. All rights reserved.

Entities:  

Year:  1996        PMID: 23194864     DOI: 10.1016/S0944-7113(96)80013-4

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  4 in total

1.  Triterpenoid resinous metabolites from the genus Boswellia: pharmacological activities and potential species-identifying properties.

Authors:  Yuxin Zhang; Zhangchi Ning; Cheng Lu; Siyu Zhao; Jianfen Wang; Baoqin Liu; Xuegong Xu; Yuanyan Liu
Journal:  Chem Cent J       Date:  2013-09-12       Impact factor: 4.215

2.  Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial.

Authors:  Ahmed Madisch; Stephan Miehlke; Otto Eichele; Jenny Mrwa; Birgit Bethke; Eberhard Kuhlisch; Elke Bästlein; Georg Wilhelms; Andrea Morgner; Bernd Wigginghaus; Manfred Stolte
Journal:  Int J Colorectal Dis       Date:  2007-09-02       Impact factor: 2.571

3.  A-90 Day Gavage Safety Assessment of Boswellia serrata in Rats.

Authors:  Pooja Singh; K Mathai Chacko; M L Aggarwal; Binu Bhat; R K Khandal; Sarwat Sultana; Binu T Kuruvilla
Journal:  Toxicol Int       Date:  2012-09

Review 4.  Review of the Chemical Composition, Pharmacological Effects, Pharmacokinetics, and Quality Control of Boswellia carterii.

Authors:  Kai Huang; Yanrong Chen; Kaiyong Liang; Xiaoyan Xu; Jing Jiang; Menghua Liu; Fenghua Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-13       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.